Search

Your search keyword '"Dawson Nancy A"' showing total 582 results
Start Over Author "Dawson Nancy A"
582 results on '"Dawson Nancy A"'

106. Molecular and functional analyses of the contractile apparatus in lymphatic muscle

Author

Muthuchamy, Mariappan, Gashev, Anatoliy, Boswell, Niven, Dawson, Nancy, Zawieja, David, and Delp, Z

Subjects
Life Sciences (General)
Abstract

Lymphatics are necessary for the generation and regulation of lymph flow. Lymphatics use phasic contractions and extrinsic compressions to generate flow; tonic contractions alter resistance. Lymphatic muscle exhibits important differences from typical vascular smooth muscle. In this study, the thoracic duct exhibited significant functional differences from mesenteric lymphatics. To understand the molecular basis for these differences, we examined the profiles of contractile proteins and their messages in mesenteric lymphatics, thoracic duct, and arterioles. Results demonstrated that mesenteric lymphatics express only SMB smooth muscle myosin heavy chain (SM-MHC), whereas thoracic duct and arterioles expressed both SMA and SMB isoforms. Both SM1 and SM2 isoforms of SM-MHC were detected in arterioles and mesenteric and thoracic lymphatics. In addition, the fetal cardiac/skeletal slow-twitch muscle-specific beta-MHC message was detected only in mesenteric lymphatics. All four actin messages, cardiac alpha-actin, vascular alpha-actin, enteric gamma-actin, and skeletal alpha-actin, were present in both mesenteric lymphatics and arterioles. However, in thoracic duct, predominantly cardiac alpha-actin and vascular alpha-actin were found. Western blot and immunohistochemical analyses corroborated the mRNA studies. However, in arterioles only vascular alpha-actin protein was detected. These data indicate that lymphatics display genotypic and phenotypic characteristics of vascular, cardiac, and visceral myocytes, which are needed to fulfill the unique roles of the lymphatic system.

Published
2003

112. CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.

Author

Tannir, Nizar M., primary, Agarwal, Neeraj, additional, Dawson, Nancy Ann, additional, Motzer, Robert J., additional, Jacobs, Carmel Maree, additional, Choueiri, Toni K., additional, Hrom, John Stewart, additional, Geynisman, Daniel M., additional, Davis, Nancy B., additional, Figlin, Robert A., additional, O'Keeffe, Mary Kathleen, additional, Parikh, Jigarkumar R., additional, Vaena, Daniel A., additional, Liu, Ping-Yu, additional, O'Keeffe, Bridget, additional, Tran, Xuan, additional, and Escudier, Bernard, additional

Published
2019
Full Text
View/download PDF

113. Non-urothelial bladder cancer: Genomic alterations and patient outcomes.

Author

Anari, Fern, primary, Miron, Benjamin, additional, Henson, Donald, additional, Arguello, David, additional, Plimack, Elizabeth R., additional, Zibelman, Matthew R., additional, Ramamurthy, Chethan, additional, Ghatalia, Pooja, additional, Heath, Elisabeth I., additional, Burgess, Earle Frederick, additional, Dawson, Nancy Ann, additional, Vaena, Daniel A., additional, Somer, Bradley G., additional, Hogan, Thomas F., additional, Hauke, Ralph J., additional, Aragon-Ching, Jeanny B., additional, and Geynisman, Daniel M., additional

Published
2019
Full Text
View/download PDF

116. Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer.

Author

Madan, Ravi A., Karzai, Fatima H., Al Harthy, Munjid, Petrylak, Daniel P., Kim, Joseph W., Arlen, Philip M., Rosner, Inger, Theoret, Marc R., Cordes, Lisa, Bilusic, Marijo, Peer, Cody J., Dawson, Nancy A., Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Chun, Guin, Owens, Helen, Marte, Jennifer L., Lee, Min‐Jung, and Tomita, Yusuke

Subjects
CASTRATION-resistant prostate cancer, DOCETAXEL, HAND-foot syndrome, PREDNISONE, DRUG efficacy
Abstract

Objective: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. Patients and Methods: This was a phase 1/2 multicentre study in patients with metastatic castration‐resistant prostate cancer (mCRPC). Docetaxel (75 mg/m2 every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg). Based on the results of the phase 1 study, the investigation was expanded into a randomized study of docetaxel with prednisone (hereafter 'docetaxel/prednisone') plus the maximum tolerated dose (MTD) of cabozantinib compared with docetaxel/prednisone alone. Results: A total of 44 men with mCRPC were enrolled in this phase 1/2 trial. An MTD of 40 mg cabozantinib plus docetaxel/prednisone was determined. Dose‐limiting toxicities were neutropenic fever and palmar‐plantar erythrodysesthesia, and there was one death attributable to a thromboembolic event. In addition, grade 3 or 4 myelosuppression, hypophosphataemia and neuropathy were seen in three or more patients. In the phase 1 study, the median time to progression (TTP) and overall survival (OS) time were 13.6 and 16.3 months, respectively. In the phase 2 study, which was terminated early because of poor accrual, the median TTP and OS favoured the combination (n = 13) compared to docetaxel/prednisone alone (n = 12; 21.0 vs 6.6 months; P = 0.035 and 23.8 vs 15.6 months; P = 0.072, respectively). Conclusion: Despite the limited number of patients in this study, preliminary data suggest that cabozantinib can be safely added to docetaxel/prednisone with possible enhanced efficacy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

117. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

Author

Dawson, Nancy A., Cooper, Michael R., Figg, William D., Headlee, Donna J., Thibault, Alain, Bergan, Raymond C., Steinberg, Seth M., Sausville, Edward A., Myers, Charles E., and Sartor, Oliver

Subjects
Prostate cancer -- Complications, Suramin sodium -- Health aspects, Prostate-specific antigen -- Measurement, Health
Abstract

Background. A prospective Phase II clinical trial was conducted to assess the clinical activity of a pharmacokinetically guided suramin regimen in patients who had documented progression of metastatic prostate cancer after hydrocortisone plus antecedent or simultaneous withdrawal of flutamide. Methods. Fifty-four patients whose disease had progressed after castration and flutamide administration were enrolled on this trial. The study was divided into two parts. Initially, 52 patients received hydrocortisone (30 mg/day) and for those patients receiving flutamide, at study entry (34 patients) flutamide was simultaneously discontinued. Forty-three patients whose disease progressed on hydrocortisone received suramin for 6-8 weeks. Six patients who progressed on hydrocortisone became ineligible for suramin due to clinical deterioration, four patients are still responding to hydrocortisone at more than 1 year, and one patient elected to postpone initiation of suramin. Suramin was given as intermittent infusions at fixed doses on days 1-5 and thereafter dosing was guided by adaptive control with feedback to maintain plasma suramin concentrations between 300-175 [mu]g/ml. Antitumor activity was assessed by prostate specific antigen (PSA) decline and soft-tissue disease response. Results. Ten patients (19%; 95% CI, 9.6%-32.5%) responded to hydrocortisone therapy with either a 50% or greater PSA decline for at least 4 weeks (9 patients) and/ or a partial response of measurable soft-tissue disease (2 patients). Five of these patients (10%) demonstrated a 80% or greater PSA decline. All responders to hydrocortisone had simultaneous flutamide withdrawal, and had been receiving flutamide as part of initial combined androgen blockade. Seven of 37 evaluable patients (19%; 95% CI, 8.0%-35.2%) responded to suramin with a 50% or greater decline in PSA for 4 weeks or longer. One patient (3%) had a 80% or greater decline in PSA. There were no soft-tissue disease responses to suramin. The median time to progression was 1.9 months for hydrocortisone therapy and 2.6 months for suramin therapy. The median survival for all patients was 14.6 months. Conclusion. Suramin has antitumor activity in metastatic prostate carcinoma independent of the therapeutic effect of hydrocortisone administration or flutamide withdrawal. The role of prior flutamide withdrawal and hydrocortisone replacement should be taken into account in future studies of suramin. Cancer 1995; 76:453-62.

Published
1995

118. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer

Author

Figg, William D., Thibault, Alain, Cooper, Michael R., Reid, Robert, Headlee, Donna, Dawson, Nancy, Kohler, David R., Reed, Eddie, and Sartor, Oliver

Subjects
Somatostatin -- Evaluation, Antineoplastic agents -- Dosage and administration, Prostate cancer, Health
Abstract

Background. Somatuline, a somatostatin analogue, has proven to be effective in several animal models of prostate cancer. Preliminary clinical studies also have suggested antitumor activity in patients with prostate cancer. The authors conducted a dose-escalation trial of 25 patients with metastatic hormone-refractory prostate cancer. Methods. Dosages of 4, 7, 10, 13, 18, and 24 mg/day were administered by continuous intravenous infusion for at least 28 days. Results. Plasma levels of insulin-like growth factor-I (IGF-I), but not those of IGF-II, declined modestly during therapy. Toxicities included grade I diarrhea, bloating, infection, nausea, and flatus. The gastrointestinal side effects were typically self-limiting and occurred during the initial portion of treatment cycles. In addition, three patients experienced grade II catheter-related infections. No clinical response was noted by either radiographic or tumor marker criteria. The maximally tolerated dose of somatuline was not determined. Conclusion. A continuous intravenous infusion of 24 mg/day of somatuline is well tolerated and could be evaluated in other types of cancer or possibly in less advanced prostate cancer, but no clinical activity was noted at this dose in patients with advanced metastatic hormone-refractory prostate cancer. Cancer 1995; 75:2159-64. Key words: prostate cancer, somatuline, somatostatin, Phase I, IGF-I, hormone-refractory, insulin-like growth factor.

Published
1995

120. A pilot trial of chemohormonal therapy for metastatic prostate carcinoma

Author

Dawson, Nancy A., Wilding, George, Weiss, Raymond B., McLeod, David G., Linehan, W. Marston, Frank, Joseph A., Jacob, Joan L., and Gelmann, Edward P.

Subjects
Hormone therapy -- Health aspects, Prostate cancer -- Care and treatment, Health
Abstract

Prostate cancer is extremely common among older men. In 1991, an estimated 122,000 new cases occurred in the US, and 32,000 men died from this disease. It is estimated that 70 percent of patients with prostate cancer will develop metastatic disease. This spread of prostate cancer to other organs, often bones, may be temporarily controlled, but, as is the case for many cancers, metastatic disease is rarely cured. Prostate cancer is sensitive to stimulation by male hormones, and therapy for metastatic prostate cancer is directed at removing this source of stimulation. This is accomplished by surgically removing the source of male hormones or by chemically interfering with the normal production of male hormones. Temporary tumor control may be achieved in 80 to 85 percent of cases, but overall survival is less than three years after treatment. A pilot study was conducted to evaluate the combination of hormonal treatment with standard chemotherapy. Fifteen patients were treated with leuprolide and flutamide, drugs that block the synthesis of male hormones (androgens) and interfere with their effects. Prior to the standard chemotherapy, the patients were primed with androgens. This priming stimulates the cancer cells which had been suppressed by the antiandrogen treatment; the idea is to catch them with the cytotoxic chemotherapeutic drugs just at they are starting to multiply again. Three patients achieved a complete response, that is, a disappearance of the symptoms of cancer, as a result of this treatment. Eight patients experienced a partial response, which is generally defined as a reduction in apparent tumor mass of at least 50 percent. The remaining four patients experienced stabilization of their cancer. The median time to disease progression among these patients was 31 months, and nine of the 15 patients are still alive after a median follow-up time of 42 months. The results of the present study were excellent and suggest that a larger trial of this combination of hormonal and chemotherapy is in order. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1992

121. Goal-Directed Achievement Through Geographic Location (GAGL) Reduces Patient Length of Stay and Adverse Events.

Author

Maniaci, Michael J., Dawson, Nancy L., Cowart, Jennifer B., Richie, Eugene M., Suryaprasad, Anil G., Hodge, David O., Joyce, Nicole E., Kernan, Carol A., Stone, Laurie A., and Burton, M. Caroline

Abstract

This prospective cohort study aimed to improve hospital outcomes through geographic location of hospitalist patients and conducting daily multidisciplinary team rounds-Goal-directed Achievements through Geographic Location (GAGL). Patients were admitted to a geographic (GAGL) study unit where daily multidisciplinary rounds took place among nursing, case management, a hospitalist, pharmacy, physical and occupational therapy, respiratory therapy, and nutrition services. A total of 985 (56.4%) patients were admitted to the GAGL study unit and 760 patients (43.6%) were admitted to non-GAGL units. Patients admitted to the GAGL study unit had a shorter average length of stay (3.64 days vs 4.35 days, P = .0001) and a lower number of risk events (91 [9.2%] vs 93 [12.2%], P = .038). There was no significant difference in 30-day readmissions, avoidable day events, or code blue team activations. GAGL provides a framework for hospital organizations to improve provider communication, hospital efficiency, and patient safety. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

125. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921

Author

Hussain, Maha, primary, Tangen, Catherine M., additional, Thompson, Ian M., additional, Swanson, Gregory P., additional, Wood, David P., additional, Sakr, Wael, additional, Dawson, Nancy A., additional, Haas, Naomi B., additional, Flaig, Thomas W., additional, Dorff, Tanya B., additional, Lin, Daniel W., additional, Crawford, E. David, additional, Quinn, David I., additional, Vogelzang, Nicholas J., additional, and Glode, L. Michael, additional

Published
2018
Full Text
View/download PDF

126. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Author

Atkins, Michael B., primary, Hodi, F. Stephen, additional, Thompson, John A., additional, McDermott, David F., additional, Hwu, Wen-Jen, additional, Lawrence, Donald P., additional, Dawson, Nancy A., additional, Wong, Deborah J., additional, Bhatia, Shailender, additional, James, Marihella, additional, Jain, Lokesh, additional, Robey, Seth, additional, Shu, Xinxin, additional, Homet Moreno, Blanca, additional, Perini, Rodolfo F., additional, Choueiri, Toni K., additional, and Ribas, Antoni, additional

Published
2018
Full Text
View/download PDF

128. TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

Author

Abida, Wassim, primary, Bryce, Alan Haruo, additional, Balar, Arjun Vasant, additional, Chatta, Gurkamal S., additional, Dawson, Nancy Ann, additional, Guancial, Elizabeth A., additional, Hussain, Arif, additional, Jha, Gautam Gopalji, additional, Lipsitz, David Uri, additional, Patnaik, Akash, additional, Petrylak, Daniel Peter, additional, Ryan, Charles J., additional, Stanton, Thomas S., additional, Vogelzang, Nicholas J., additional, Zhang, Jingsong, additional, Simmons, Andrew, additional, Go, Jowell, additional, Golsorkhi, Tony, additional, Chowdhury, Simon, additional, and Scher, Howard I., additional

Published
2018
Full Text
View/download PDF

134. Correspondence

Author

Nolan, Dan, Schulman, Christopher F., Cohen, Gerry, Higgins, A. Stanley, Sprankle, Lori, Robbins, Lenny, Dandridge,, E. P., Goble, S., Wise, Daniel E., Wellnitz, Barbara L., Jacobs, Christine, Fuchs, Betsy W., Dawson, Nancy, Hedtke, John V., and Fedun, Bohdan

Published
1991

135. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Author

Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F, IMvigor210 Study Group, Balar, Av, Rosenberg, Je, Powles, T, Petrylak, Dp, Bellmunt, J, Loriot, Y, Necchi, A, Hoffman-Censits, J, Perez-Gracia, Jl, Dawson, Na, van der Heijden, M, Dreicer, R, Srinivas, S, Retz, Mm, Joseph, Rw, Drakaki, A, Vaishampayan, Un, Sridhar, S, Quinn, Di, Duran, I, Shaffer, Dr, Eigl, Bj, Grivas, Pd, Yu, Ey, Li, S, Kadel, Ee, Boyd, Z, Bourgon, R, Hegde, P, Mariathasan, S, Thastrom, A, Abidoye, Oo, Fine, Gd, and Bajorin, Df

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Urologic Neoplasms, Metastatic Urothelial Carcinoma, Phases of clinical research, Antineoplastic Agents, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Internal medicine, Clinical endpoint, medicine, Carcinoma, Biomarkers, Tumor, Humans, Infusions, Intravenous, Response Evaluation Criteria in Solid Tumors, Aged, Aged, 80 and over, Carcinoma, Transitional Cell, business.industry, Contraindications, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Discontinuation, Surgery, 030104 developmental biology, Tolerability, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Female, Cisplatin, business
Abstract

Summary Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. Methods For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652. Findings Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients. Interpretation Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer. Funding F Hoffmann-La Roche, Genentech.

Published
2016

136. Patient portal use and hospital outcomes

Author

Dumitrascu, Adrian G, primary, Burton, M Caroline, additional, Dawson, Nancy L, additional, Thomas, Colleen S, additional, Nordan, Lisa M, additional, Greig, Hope E, additional, Aljabri, Duaa I, additional, and Naessens, James M, additional

Published
2017
Full Text
View/download PDF

140. Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921.

Author

Hussain, Maha, primary, Tangen, Catherine M., additional, Thompson, Ian Murchie, additional, Swanson, Gregory P., additional, Wood, David Peter, additional, Sakr, Wael, additional, Dawson, Nancy Ann, additional, Haas, Naomi B., additional, Flaig, Thomas W., additional, Dorff, Tanya B., additional, Lin, Daniel W., additional, Crawford, E. David, additional, Quinn, David I., additional, Vogelzang, Nicholas J., additional, and Glode, L. Michael, additional

Published
2017
Full Text
View/download PDF

143. Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124.

Author

Glode, L. Michael, primary, Tangen, Catherine M., additional, Hussain, Maha, additional, Swanson, Gregory P., additional, Wood, David Peter, additional, Sakr, Wael, additional, Dawson, Nancy Ann, additional, Haas, Naomi B., additional, Flaig, Thomas W., additional, Dorff, Tanya B., additional, Lin, Daniel W., additional, Crawford, E. David, additional, Quinn, David I., additional, Vogelzang, Nicholas J., additional, and Thompson, Ian Murchie, additional

Published
2017
Full Text
View/download PDF

144. Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).

Author

Small, Eric Jay, primary, Lance, Raymond S., additional, Redfern, Charles H., additional, Millard, Frederick E., additional, Gardner, Thomas A., additional, Dawson, Nancy Ann, additional, Fong, Lawrence, additional, Karsh, Lawrence Ivan, additional, Corman, John M., additional, Nordquist, Luke T., additional, Murdock, Myron I, additional, Curti, Brendan D., additional, Chang, Nancy N., additional, and Shore, Neal D., additional

Published
2017
Full Text
View/download PDF

145. Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.

Author

Choueiri, Toni K., primary, Hodi, F. Stephen, additional, Thompson, John A., additional, McDermott, David F., additional, Hwu, Wen-Jen, additional, Lawrence, Donald P., additional, Dawson, Nancy Ann, additional, Wong, Deborah Jean Lee, additional, Bhatia, Shailender, additional, James, Marihella, additional, Shu, Xinxin, additional, Homet Moreno, Blanca, additional, Ibrahim, Nageatte, additional, Perini, Rodolfo F., additional, Ribas, Antoni, additional, and Atkins, Michael B., additional

Published
2017
Full Text
View/download PDF

147. Reducing unnecessary testing: an intervention to improve resident ordering practices

Author

Melendez-Rosado, Jose, primary, Thompson, Kristine M, additional, Cowdell, Jed C, additional, Sanchez Alvarez, Catalina, additional, Ung, Ryan L, additional, Villanueva, Armando, additional, Jeffers, Kayin B, additional, Imam, Jaafer S, additional, Mitkov, Mario V, additional, Kaleem, Tasneem A, additional, Jacob, Lewis, additional, and Dawson, Nancy L, additional

Published
2017
Full Text
View/download PDF

149. Alice Allison Dunnigan: led the fight for black journalists

Author

Dawson, Nancy J.

Subjects
African American journalists -- Biography, African American journalists -- Works, African American journalists -- Appreciation, Ethnic, cultural, racial issues/studies, Law, Political science
Published
2007

Catalog

Books, media, physical & digital resources
See catalog results